DeepMed Research

Chong Kun Dang Pharmaceutical Corp.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Public

Established: 1941-01-01

Employees: 2.3K

Market Cap: -

Website: http://www.ckdpharm.com

Clinical Trials

Clinical Trial to Evaluate the Efficacy and Safety of CKD-495 Tablet

Phase 2

Completed

Conditions: Gastritis

Interventions: Drug: CKD-495 75mg
Drug: CKD-495 150mg
Drug: Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg
Drug: Rebamipide 100mg
Drug: Placebo of the CKD-495 150mg
Drug: Placebo of the CKD-495 75mg
Drug: Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg
Drug: Placebo of the Rebamipide 100mg

First Posted Date: 2018-02-19

Last Posted Date: 2018-10-31

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 250

Registration Number: NCT03437785

Locations: 🇰🇷
Chonnam National University Hospital, Gwangju, Donggu, Jebongro, Korea, Republic of
🇰🇷
Hallym University Chuncheon Seonsim Hospital, Chuncheon, Korea, Republic of
🇰🇷
Yeungnam University Medical Center, Daegu, Korea, Republic of

and more 13 locations

CKD-11101 Phase 3 SC Study

Phase 3

Completed

Conditions: Anemia of Chronic Kidney Disease

Interventions: Biological: CKD-11101(Darbepoetin alfa)
Biological: NESP(Darbepoetin alfa)

First Posted Date: 2018-02-13

Last Posted Date: 2018-02-13

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 248

Registration Number: NCT03431623

CKD-11101 Phase 3 IV Study in Patients Who Had Renal Anemia Receiving Hemodialysis

Phase 3

Completed

Conditions: Anemia of Chronic Kidney Disease

Interventions: Biological: NESP
Biological: CKD-11101

First Posted Date: 2018-02-09

Last Posted Date: 2018-02-09

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 403

Registration Number: NCT03428594

A Clinical Trial to Assess the Effects of Food on the Bioavailability of CKD-337

Phase 1

Completed

Conditions: Dyslipidemias

Interventions: Dietary Supplement: High fat diet
Drug: CKD-337

First Posted Date: 2017-12-26

Last Posted Date: 2017-12-27

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 16

Registration Number: NCT03382756

Locations: 🇰🇷
Dong-A University Hospital, Busan, Seo-gu, Korea, Republic of

A Clinical Trial to Compare Safety and Pharmacokinetic Characteristics of CKD-337

Phase 1

Completed

Conditions: Dyslipidemias

Interventions: Drug: Active Comparator(Atorvastatin Calcium Trihydrate+Fenofibrate)
Drug: Test drug(CKD-337)

First Posted Date: 2017-11-17

Last Posted Date: 2017-12-19

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 60

Registration Number: NCT03346187

Locations: 🇰🇷
Dong-A University Hospital, Busan, Seo-gu, Korea, Republic of

Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients

Phase 3

Completed

Conditions: Benign Prostatic Hyperplasia

Interventions: Drug: Tamsulosin 0.2mg
Drug: Tadalafil 5mg

First Posted Date: 2017-08-11

Last Posted Date: 2017-08-11

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 455

Registration Number: NCT03246880

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

CKD-841 Pharmacokinetic/Pharmacodynamic Study

Phase 1

Completed

Conditions: Postmenopausal Disorder

Interventions: Drug: LeuplinⓡInj
Drug: CKD-841

First Posted Date: 2017-07-31

Last Posted Date: 2017-07-31

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 13

Registration Number: NCT03233932

Locations: 🇰🇷
Severance Hospital, Seoul, Yonsei-ro, Seodaemun-gu 50-1, Korea, Republic of

Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519

Phase 1

Completed

Conditions: Dyslipidemia

Interventions: Drug: CKD-519
Drug: Placebo

First Posted Date: 2017-07-07

Last Posted Date: 2017-07-07

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 18

Registration Number: NCT03210649

Locations: 🇰🇷
Severance Hospital, Seoul, Seodaemun-gu, Korea, Republic of

A Study to Compare PK, PD and Safety of CKD-381 in Healthy Subjects

Phase 1

Completed

Conditions: GERD

Interventions: Drug: CKD-381
Drug: Nexium

First Posted Date: 2017-07-07

Last Posted Date: 2017-11-21

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 41

Registration Number: NCT03211143

Locations: 🇰🇷
Severance Hospital, Seoul, Korea, Republic of

Study to Evaluate the Drug Interaction Between CKD-519 and Rosuvastatin in Healthy Male Subjects

Phase 1

Completed

Conditions: Dyslipidemias

Interventions: Drug: Rosuvastatin 20 mg
Drug: CKD-519 200 mg
Drug: Rosuvastatin 20 mg & CKD-519 200 mg

First Posted Date: 2017-06-05

Last Posted Date: 2017-07-07

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 30

Registration Number: NCT03175835

Locations: 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy